217 related articles for article (PubMed ID: 26543760)
1. Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review.
Watanabe J
Springerplus; 2015; 4():625. PubMed ID: 26543760
[TBL] [Abstract][Full Text] [Related]
2. A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
Kimura K; Iwamoto M; Tanaka S; Yamamoto D; Yoshidome K; Ogura H; Terasawa R; Matsunami N; Takahashi Y; Nitta T; Morimoto T; Fujioka H; Kawaguchi K; Uchiyama K
Cancer Chemother Pharmacol; 2018 May; 81(5):923-933. PubMed ID: 29594360
[TBL] [Abstract][Full Text] [Related]
3. A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer.
Takashima T; Tokunaga S; Tei S; Nishimura S; Kawajiri H; Kashiwagi S; Yamagata S; Noda S; Nishimori T; Mizuyama Y; Sunami T; Tezuka K; Ikeda K; Ogawa Y; Onoda N; Ishikawa T; Kudoh S; Takada M; Hirakawa K
Springerplus; 2016; 5():164. PubMed ID: 27026861
[TBL] [Abstract][Full Text] [Related]
4. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
[TBL] [Abstract][Full Text] [Related]
5. Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study.
Jiang M; Shao B; Wan D; Liu J; He M; Chai Y; Sang D; Wang J; Ma F; Fan Y; Yuan P; Xu B; Li Q
Ther Adv Med Oncol; 2023; 15():17588359231204856. PubMed ID: 37841751
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens.
Kikuchi Y; Uchida Y; Shirakawa K; Kanauchi H; Niwa T; Nishioka K; Tada K; Hashimoto M; Yasuda H; Sugiura R; Kawabata H; Seto Y; Ogawa T
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e231-e237. PubMed ID: 29498210
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
Maeda S; Saimura M; Minami S; Kurashita K; Nishimura R; Kai Y; Yano H; Mashino K; Mitsuyama S; Shimokawa M; Tamura K;
Breast; 2017 Apr; 32():66-72. PubMed ID: 28056400
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness, safety, and impact on quality of life of eribulin-based therapy in heavily pretreated patients with metastatic breast cancer: A real-world analysis.
Gui X; Liang X; Li H
Cancer Med; 2023 Aug; 12(16):16793-16804. PubMed ID: 37403746
[TBL] [Abstract][Full Text] [Related]
9. Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer.
Shingaki S; Kogawa T; Shimokawa M; Harano K; Naito Y; Kusuhara S; Fujimoto Y; Matsubara N; Hosono A; Mukai H; Onishi T; Hojo T; Mukohara T
J Cancer; 2020; 11(14):4099-4105. PubMed ID: 32368292
[No Abstract] [Full Text] [Related]
10. Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study.
Puhalla S; Wilks S; Brufsky AM; O'Shaughnessy J; Schwartzberg LS; Berrak E; Song J; Vahdat L
Breast Cancer (Dove Med Press); 2016; 8():231-239. PubMed ID: 27994483
[TBL] [Abstract][Full Text] [Related]
11. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
Inoue K; Saito T; Okubo K; Kimizuka K; Yamada H; Sakurai T; Ishizuna K; Hata S; Kai T; Kurosumi M
Breast Cancer Res Treat; 2016 Jun; 157(2):295-305. PubMed ID: 27125669
[TBL] [Abstract][Full Text] [Related]
12. Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.
Aftimos P; Polastro L; Ameye L; Jungels C; Vakili J; Paesmans M; van den Eerenbeemt J; Buttice A; Gombos A; de Valeriola D; Gil T; Piccart-Gebhart M; Awada A
Eur J Cancer; 2016 Jun; 60():117-24. PubMed ID: 27107326
[TBL] [Abstract][Full Text] [Related]
13. Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.
Inoue K; Ninomiya J; Saito T; Okubo K; Nakakuma T; Yamada H; Kimizuka K; Higuchi T;
Invest New Drugs; 2019 Jun; 37(3):538-547. PubMed ID: 30848403
[TBL] [Abstract][Full Text] [Related]
14. Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study.
Nakamoto S; Watanabe J; Ohtani S; Morita S; Ikeda M
BMC Cancer; 2022 Jan; 22(1):31. PubMed ID: 34980019
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study.
Zhao Y; Xie N; Li W; Chen W; Lv Z; Zheng Y; Sun T; Liu J; Zhang J; Hu S; Wang Y; Gong C; Li Y; Xie Y; Ge R; Xu F; Wang B
Ther Adv Med Oncol; 2021; 13():17588359211030210. PubMed ID: 34290830
[TBL] [Abstract][Full Text] [Related]
16. Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies.
O'Shaughnessy J; McIntyre K; Schwartzberg L; Wilks S; Puhalla S; Berrak E; Song J; Vahdat L
Springerplus; 2015; 4():532. PubMed ID: 26413438
[TBL] [Abstract][Full Text] [Related]
17. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.
Manso L; Moreno Antón F; Izarzugaza Perón Y; Delgado Mingorance JI; Borrega García P; Echarri González MJ; Martínez-Jañez N; López-González A; Olier Garate C; Ballesteros García A; Chacón López-Muñíz I; Ciruelos Gil E; García-Sáenz JA; Paz-Ares L
Breast J; 2019 Mar; 25(2):219-225. PubMed ID: 30734437
[TBL] [Abstract][Full Text] [Related]
18. Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study.
Adamo V; Ricciardi GRR; Giuffrida D; Scandurra G; Russo A; Blasi L; Spadaro P; Iacono C; Soto Parra HJ; Savarino A; Ferraú F; Zerilli F; Verderame F; Butera A; Santangelo C; Franchina V; Caruso M
Ther Adv Med Oncol; 2019; 11():1758835919895755. PubMed ID: 31903098
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea.
Tremblay G; Majethia U; Breeze JL; Kontoudis I; Park J
Clinicoecon Outcomes Res; 2016; 8():485-493. PubMed ID: 27698565
[TBL] [Abstract][Full Text] [Related]
20. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
